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Objectives. Postischemic contractile dysfunction in the heart
may be due, in part, to isoprostanes, thought to accumulate
during myocardial reperfusion. This study tested whether cyclo-
oxygenase (COX) inhibitors increase the amount of isoprostanes
and, consequently, lead to deterioration of postischemic heart
function.
Background. Isoprostanes are bioactive prostaglandin-like
compounds that are formed in vivo directly by free radical–
catalyzed peroxidation of arachidonic acid. In particular, 8-iso-
prostaglandin (PG) F2a is a potent vasoconstrictor.
Methods. Isolated working guinea pig hearts underwent 30-min
low flow ischemia followed by reperfusion, 15 min in a nonworking
mode and 20 min performing pressure–volume work. Hearts were
perfused with or without 100 mmol/liter acetylsalicylic acid (ASA),
3 or 10 mmol/liter indomethacin or 1 mmol/liter SQ 29548, a
thromboxane-A2 (TxA2) receptor antagonist able to abolish the
vasoconstrictive actions of 8-iso-PGF2a. External heart work
(EHW) and coronary resistance were compared before and after
ischemia. Coronary release and tissue content of 8-iso-PGF2a
were also determined.
Results. During reperfusion, 8-iso-PGF2a release increased
tenfold compared with the preischemic value in all groups.
However, in ASA- and indomethacin-treated hearts, 8-iso-PGF2a
levels were ;15-fold higher than in control hearts (5.4 vs. 0.35
pg/ml, respectively). Postischemic tissue levels of 8-iso-PGF2a
were also markedly higher: 215 (indomethacin) and 301 (ASA)
pg/ml g dry weight versus 43 pg/mg dry weight for control hearts
(p < 0.05). Treatment of hearts with COX inhibitor led to a
reduction in recovery of EHW (40% vs. 71%, p < 0.05) and seemed
to be due to impaired myocardial oxygenation: Coronary venous
oxygen was lower (67% of control values), whereas anaerobic
metabolism (lactate release vs. pyruvate consumption) was en-
hanced. Coronary resistance was correspondingly elevated (164%
of control values). SQ 29548 caused all variables to revert to
control values.
Conclusions. These data demonstrate that in the guinea pig
heart, COX-inhibiting drugs exacerbate loss of cardiac function
after ischemia. The enhanced production of isoprostanes favors
coronary vasoconstriction and leads to myocardial oxygen depri-
vation.
(J Am Coll Cardiol 1998;31:1687–94)
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Cardiac synthesis and release of various enzymatically formed
eicosanoids during and after ischemia have been well docu-
mented (1–3). However, arachidonic acid (AA) is not only
metabolized by enzymes such as cyclooxygenase (COX), but is
also subject to direct oxidative modification (4). The F2-
isoprostanes, a family of prostaglandin (PG) F2a-isomers pro-
duced by the random oxidation of AA in tissue phospholipids
by oxygen radicals, are present in the plasma and urine under
normal conditions and are elevated by oxidative stress (5). One
of these compounds, 8-iso-PGF2a, has been shown (6–8) to be
a potent renal, pulmonary and coronary vasoconstrictor, effects
that are prevented by the thromboxane-A2 (TxA2) receptor
antagonist SQ 29548.
Early attempts at reducing myocardial ischemic damage by
inhibiting TxA2 formation with COX inhibitors such as acetyl-
salicylic acid (ASA) were relatively unsuccessful (9). Because
8-iso-PGF2a may act through TxA2 or closely related recep-
tors, it is of interest that thromboxane receptor antagonists
have been found (10) to exert salutary effects in situations of
ischemia–reperfusion that are difficult to explain by antago-
nism of the actions of TxA2 itself. In contrast, postischemic
reperfusion is known to be associated with a burst of oxygen
free radical formation. These observations have led us to
speculate that the marginal profit of COX inhibition for
ischemic myocardium is a consequence of shunting of AA
(which then cannot be metabolized to PGI2, PGD2, PGH2,
PGE2 and TxA2) toward the free radical– derived
prostaglandin-like compounds, such as F2-isoprostanes. To
determine whether enhanced formation of 8-iso-PGF2a occurs
in hearts during treatment with COX-inhibiting drugs and
whether this phenomenon influences postischemic function, an
isolated heart model of low flow myocardial ischemia followed
by reperfusion was used. We examined the effects of ASA and
indomethacin administered either alone or simultaneously
with the TxA2 receptor antagonist SQ 29548.
The results of the present study provide evidence for a role
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of isoprostanes in modulating the extent of acute ischemia–
reperfusion injury in the presence of COX inhibitors and
identify a pharmacologic interaction of potential therapeutic
importance, namely, application of a “thromboxane” receptor
antagonist also able to block isoprostane-mediated effects.
Methods
Working heart preparation. The investigation was per-
formed in conformance with the “Position of the American
Heart Association on Research Animal Use” adopted by the
Association in November 1984. Isolated hearts from male
guinea pigs (230 to 280 g) were prepared as previously
described in detail in reports from this laboratory (11). Briefly,
animals were stunned by neck dislocation, and the hearts were
initially retrogradely perfused through the aorta at a constant
pressure of 80 cm H2O according to the Langendorff technique
with a nonrecirculating modified Krebs-Henseleit buffer
(KHB) gassed with 94.6% oxygen and 5.4% carbon dioxide
(37°C, pH 7.4). The caval and azygos veins were ligated. The
pulmonary artery was cannulated to enable measurement of
coronary flow and PO2 in the coronary venous effluent. The left
atrium was cannulated through an opening formed by uniting
the four pulmonary vein orifices, permitting natural atrial
contraction and control of left ventricular filling.
Physiologic measurements. The aortic pressure pulse and
left ventricular filling pressure were measured directly using
pressure transducers (model 1050 BP, ADInstruments, Aus-
tralia). Mean aortic pressure, heart rate and ejection time of
stroke volume were derived from the pressure signal. Coronary
flow and aortic flow were determined by means of a two-
channel flowmeter (model T 206, Transonic Systems Inc).
Partial pressure of oxygen in the coronary venous effluent
(PvO2) was measured using a Clark O2 microelectrode
(Bachofer, Reutlingen, Germany). To characterize cardiac
function, external heart work (EHW) was defined as the sum
of pressure–volume work and acceleration work (12) and
cardiac output as the sum of aortic flow and coronary flow. To
calculate myocardial oxygen consumption (MVO2) (per g heart
weight), coronary flow and differences in PO2 of the perfusate
(PaO2, held constant at 630 mm Hg) and PvO2 were used (13).
Experimental protocol. The perfusion protocol is schemat-
ically outlined in Figure 1 and was chosen to ensure only mild
loss of postischemic function under control conditions, facili-
tating the detection of deleterious effects of COX inhibition.
After an initial 20-min work phase (work phase 1) under
strictly standardized conditions (mean left ventricular filling
pressure 8.8 mm Hg, mean arterial pressure 63 mm Hg) during
which baseline hemodynamic variables were obtained, normo-
thermic low flow ischemia was induced by perfusing hearts for
30 min in the Langendorff mode at a coronary flow of 1 ml/min,
equivalent to ;10% of the spontaneous coronary flow during
work. The following 15-min phase of reperfusion with the
oxygenated KHB was initiated by elevating the coronary flow
to a constant 5 ml/min, with the hearts remaining in the
nonworking Langendorff mode of perfusion. In the first 5 min
of this reperfusion interval, coronary venous effluent was
collected to measure the early myocardial pyruvate consump-
tion and the release of lactate and 8-iso-PGF2a. Hearts were
then resubjected to pressure–volume work for a second period
of 20 min (work phase 2) and all hemodynamic variables (see
Physiologic measurements) were again determined. Recovery
of a given variable was defined as the postischemic value versus
the preischemic value after 20 min of work, expressed in
percent. Control hearts (n 5 6) received no additives to the
perfusate. In all experiments involving the COX inhibitors
ASA (n 5 6) or indomethacin (n 5 4 for each concentration),
these agents were applied throughout the experiment. Stock
solution of indomethacin was added directly to the perfusion
medium to achieve final concentrations of 3 or 10 mmol/liter.
The fresh stock solutions of ASA and SQ 29548 were infused
either into the left atrial cannula (working phase) or the aortic
Abbreviations and Acronyms
AA 5 arachidonic acid
ASA 5 acetylsalicylic acid
COX 5 cyclooxygenase
EHW 5 external heart work
KHB 5 Krebs-Henseleit buffer
MVO2 5 myocardial oxygen consumption
PvO2 5 partial pressure of oxygen in the coronary venous effluent
R 5 reperfusion
TxA2 5 thromboxane-A2
Figure 1. Perfusion protocol. After an initial period (20 min) of
pressure–volume work (Work 1), hearts were subjected to 30 min of
low flow ischemia (1 ml/min), followed by the reperfusion phase (R)
(15 min), during the first 5 min of which coronary venous effluent was
collected, and a second period of 20 min of pressure–volume work
(Work 2). The following groups were investigated: Control 5 perfu-
sion with Krebs-Henseleit buffer alone; ASA 5 100 mmol/liter ASA
applied throughout; INDO 5 3 or 10 mmol/liter indomethacin applied
throughout; SQ 5 1 mmol/liter SQ 29548 applied throughout;
ASA1SQ 5 ASA plus SQ 29548 applied throughout; ASA1SQ(R) 5
ASA throughout but SQ 29548 applied only from the onset of the
reperfusion period; INDO1SQ(R) 5 10 mmol/liter indomethacin
throughout but SQ 29548 applied only from the onset of the reperfu-
sion period.
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feed line (Langendorff phase) at rates calculated to yield the
desired end concentration in the cardiac perfusate. The choice
of concentrations of ASA and indomethacin was based on
reports in which, after 15 min of application, 100 mmol/liter
ASA (14) and 10 mmol/liter indomethacin (15) sufficed to
abolish irreversibly the synthesis of COX products of endothe-
lial cells.
SQ 29548 was infused either at the onset of work phase 1
(SQ 29548 alone, n 5 4; ASA plus SQ 29548, n 5 6) and then
continued until the end of the study protocol or was given only
at the onset of reperfusion (ASA plus SQ 29548[R] and
indomethacin plus SQ 29548[R], n 5 4 each). The selected
concentration of 1 mmol/liter of SQ 29548, by itself, has not
been associated with alterations in ventricular performance but
has conferred beneficial effects on isolated guinea pig hearts
perfused with exogenous isoprostanes (8).
Determination of lactate release and pyruvate consump-
tion. Coronary venous effluent was collected through the
pulmonary artery at the end of work phase 1 and in the early
reperfusion period (first 5 min), and aliquots were stored at
220°C to await analysis. The concentrations of lactate and
pyruvate were determined by high performance liquid chroma-
tography (8). The concentration values, multiplied by the
coronary flow rate, yielded cardiac release. Subtraction of the
pyruvate value from the inflow concentration (0.3 mmol/liter)
before multiplication yielded cardiac consumption.
Determination of 8-iso-PGF2a. Measurements of 8-iso-
PGF2a concentrations in the coronary effluent were performed
using a commercially available enzyme immunoassay (SPI-
BIO, Massey Cedex, France). Effluent was collected at the end
of work phase 1 and during the first 5 min of reperfusion and
stored at 280°C until analyzed. At the end of the experiment,
four hearts each from the control, ASA and indomethacin
groups were clamped with aluminum tongs cooled to the
temperature of liquid nitrogen and stored at 280°C until
analyzed. Frozen ventricular tissue was pulverized under liquid
nitrogen. A portion of the powdered tissue was used to
determine the dry/wet weight ratio. Extraction of 8-iso-PGF2a
from ;100 mg of frozen powdered ventricular tissue was
achieved with 3 ml of 0.5 mol/liter perchloric acid. After
neutralization, isoprostane levels were determined by enzyme
immunoassay (RD-Systems, Wiesbaden, Germany). All results
were expressed in pg/mg dry heart weight. The average recov-
ery of 8-iso-PGF2a spiked into tissue samples was 106%. All
values were corrected by this amount.
Materials. SQ 29548 was purchased from SPI-BIO and
ASA and indomethacin from Sigma (Deisenhofen, Germany).
All other reagents were obtained from Merck (Darmstadt,
Germany). SQ 29548 (2.58 mmol/liter) was dissolved in dis-
tilled water and ASA (100 mmol/liter) and indomethacin
(1 mmol/liter) in KHB solution immediately before application
to the hearts; all three solutions were slightly alkalinized with
NaOH (pH ,8.5).
Statistical analysis. Results are expressed as mean value 6
SEM, and the number of experiments varied from four to six.
Statistical evaluation was carried out by one-way analysis of
variance with post hoc comparison by the Student-Newman-
Keul test. A p value ,0.05 was considered statistically signifi-
cant.
Results
Hemodynamic data. Hemodynamic and functional vari-
ables are summarized in Table 1. There were no statistically
significant differences between the various groups for any
variable measured at the end of work phase 1.
After exposure of control hearts to 30 min low flow
ischemia, coronary flow and aortic flow recovered to 75 6 2%
and 72 6 3%, respectively, at the end of work phase 2, whereas
heart rate recovered fully (Table 1). The difference from work
phase 1 in cardiac output resulted in a modest but significant
reduction in EHW (Table 1, Fig. 2). Coronary vascular resis-
tance, calculated from the mean aortic pressure/coronary flow
ratio, rose from the 5th to the 15th minute of reperfusion
(Table 2); this taken as a sign of waning reactive hyperemia.
Coronary resistance rose further in work phase 2.
Effect of COX inhibition. Treatment of hearts with ASA at
a concentration fully inhibiting COX did not modify myocar-
dial contractility during the preischemic period (Table 1).
However, ASA significantly worsened the recovery of coronary
flow and aortic flow (Table 1) and induced a significantly lower
recovery of EHW of only 40 6 6% versus 71 6 3% for control
hearts (Fig. 2). Furthermore, in the presence of ASA, coronary
vascular resistance during the early reperfusion period (first
5 min) and in work phase 2 was greater than that in the
untreated preparations (Table 2).
Effects similar to those produced by ASA were obtained
with indomethacin, which, with increasing concentrations,
caused a reduction in postischemic recovery of all variables
except heart rate (Table 1). Coronary flow recovered to 59 6
3%, aortic flow to 52 6 5% and EHW to 54 6 5% at an
indomethacin concentration of 3 mmol/liter (data not shown)
versus 57 6 4%, 47 6 7% and 48 6 6%, respectively, with 10
mmol/liter indomethacin (Table 1, Fig. 2). As in the case of
ASA, coronary vascular resistance during restoration of flow
after 30 min of ischemia as well as during work phase 2 was
markedly higher in the indomethacin group than in the control
group (Table 2).
Additional TxA2 receptor blockade. The “thromboxane” re-
ceptor antagonist SQ 29548 did not significantly alter the
pattern of functional recovery observed in the control group,
and there was even a modest trend toward a beneficial effect
(Table 1, Fig. 2). Thus, functional recovery of all measured
variables after ischemia and reperfusion was significantly
higher in the SQ 29548 group than in the ASA and indometh-
acin groups (Tables 1 and 2, Fig. 2). The addition of SQ to
ASA throughout the experiment resulted in improved recovery
(p , 0.05) of EHW (79 6 2% vs. 64 6 3%), coronary flow
(75 6 3% vs. 55 6 1%) and aortic flow (67 6 1% vs. 39 6 7%)
(Table 1, Fig. 2). Importantly, SQ 29548 improved postisch-
emic myocardial recovery of ASA- and indomethacin-treated
hearts to control levels. This improvement was also seen when
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the application of SQ 29548 started exclusively with reperfu-
sion (Table 1, Fig. 2). In addition, the ASA- and indomethacin-
induced elevation of coronary resistance during the initial
reperfusion phase was abolished (Table 2).
Metabolic data. Myocardial oxygenation. MVO2 of control
hearts and hearts perfused with SQ 29548 decreased during
work phase 2 to ;80% of that during work phase 1 (Table 1).
This decrease corresponded well with the decreased perfor-
mance of EHW in these two groups of hearts (Fig. 2). In
contrast, in hearts perfused with inhibitors of COX, postisch-
emic MVO2 amounted to ;60% of the preischemic value,
Figure 2. Recovery of EHW after ischemia and reperfusion. EHW
determined at the end of work phase 2 is expressed as a percentage of
the value in work phase 1. Columns 5 mean value 6 SEM (n 5 4 to
6). *p , 0.05 versus control (CON) and SQ groups. †p , 0.05 versus
ASA1SQ group. ‡p , 0.05 versus INDO1SQ(R) group. Other
abbreviations as in Figure 1.
Table 1. Preischemic and Postischemic Functional and Hemodynamic Variables of Different Groups of
Hearts
Group and Work Phase
Heart Rate
(beats/min)
Coronary Flow
(ml/min per g)
Aortic Flow
(ml/min per g)
EHW
(mJ/min per g)
MVO2
(mmol/min per g)
Control (n 5 6)
W1 249 6 5 10.6 6 0.6 39.9 6 3.5 425 6 32 7.1 6 0.5
W2 243 6 6 8.0 6 0.2* 29.0 6 3.1* 304 6 28* 5.6 6 0.1*
SQ 29548 (n 5 4)
W1 256 6 5 10.6 6 0.8 39.7 6 2.0 407 6 21 7.0 6 0.5
W2 238 6 7 8.5 6 1.0 30.1 6 3.2* 312 6 32* 5.8 6 0.7
ASA (n 5 6)
W1 248 6 5 10.1 6 0.7 36.1 6 3.2 377 6 29 6.7 6 0.5
W2 232 6 8 5.5 6 0.5*†‡§ 14.2 6 3.4*†§ 154 6 31*†‡§ 4.0 6 0.3*†‡§
Indo (n 5 4)
W1 249 6 3 10.5 6 1.0 40.3 6 5.2 414 6 41 7.0 6 0.5
W2 237 6 6 6.1 6 1.0* 19.1 6 5.5* 203 6 43*# 4.4 6 0.7*
ASA1SQ 29548 (n 5 6)
W1 240 6 6 9.9 6 0.5 34.8 6 3.6 365 6 33 6.6 6 0.3
W2 227 6 10 7.3 6 0.4* 23.3 6 2.4* 248 6 22* 5.3 6 0.3*
ASA1SQ 29548 (R) (n 5 4)
W1 246 6 6 10.3 6 0.6 41.5 6 4.4 423 6 39 6.9 6 0.4
W2 233 6 12 7.5 6 0.5* 28.5 6 3.9 292 6 35* 5.4 6 0.4*
Indo1SQ 29548 (R) (n 5 4)
W1 244 6 10 11.1 6 1.0 45.7 6 2.1 464 6 24 7.4 6 0.7
W2 227 6 15 7.8 6 0.3* 31.3 6 1.4* 317 6 12* 5.6 6 0.3*
*p , 0.05 versus work phase 1. †p , 0.05 versus control and SQ 29548 groups at matched time point. ‡p , 0.05 versus
ASA1SQ 29548 group at matched time point. §p , 0.05 versus ASA1SQ 29548 (R) at matched time point. #p , 0.05
versus Indo1SQ 29548 (R) at matched time point. Data presented are mean value 6 SEM. ASA 5 acetyl salicylic acid;
EHW 5 external heart work; Indo 5 indomethacin; MVO2 5 myocardial oxygen consumption; R 5 SQ 29548
(1 mmol/liter) applied from the onset of reperfusion; all other drugs were applied throughout the experiment (ASA:
100 mmol/liter; Indo: 10 mmol/liter); W1 5 work phase 1; W2 5 work phase 2.
Table 2. Coronary Vascular Resistance Determined at End of Early
and Late Phase of Reperfusion and at End of Postischemic
Work Phase
Group
Coronary Vascular
Resistance
(mm Hg/ml per min)*
W2R1 R2
Control (n 5 6) 4.6 6 0.3 6.6 6 0.6 7.2 6 0.2
SQ 29548 (n 5 4) 4.0 6 0.2 6.1 6 0.4 6.5 6 0.9
ASA (n 5 6) 6.5 6 0.5†‡ 7.5 6 0.3 11.8 6 0.8†‡
Indo (n 5 4) 6.3 6 0.3†§ 7.4 6 1.8 10.2 6 0.9†§
ASA1SQ 29548 (n 5 6) 4.4 6 0.3 6.3 6 0.5 7.9 6 0.4
ASA1SQ 29548 (R) (n 5 4) 4.1 6 0.5 6.5 6 0.6 7.8 6 0.7
Indo1SQ 29548 (R) (n 5 4) 4.6 6 0.5 6.9 6 0.5 7.4 6 0.3
*Coronary vascular resistance was measured after the first 5 min (R1) and
subsequent 10 min of reperfusion (R2) and after the second work phase (W2).
†p , 0.05 versus control and SQ 29548 groups. ‡p , 0.05 versus ASA1SQ 29548
and ASA1SQ 29548 (R) groups. §p , 0.05 versus Indo1SQ 29548 (R) group.
Data presented are mean value 6 SEM. ASA 5 acetylsalicylic acid 100
mmol/liter applied throughout; Indo 5 indomethacin (10 mmol/liter applied
throughout); R 5 SQ 29548 (1 mmol/liter) applied only from the onset of
reperfusion.
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whereas EHW levels had recovered to only 40% to 50%. The
addition of SQ 29548 restored MVO2 (and EHW) to control
levels (Table 1).
To address whether reduced MVO2 was in accordance with
decreased function or was the cause of the functional deteri-
oration of hearts perfused with ASA or indomethacin, we
compared coronary flow during work phase 2 with the PvO2 of
the respective hearts (Fig. 3). Figure 3 (top panel) clearly
shows that coronary flow recovered to only ;55% of the
preischemic value in hearts treated with COX inhibitors. SQ
29548 restored recovery of coronary flow to control levels.
PvO2 (Fig. 3, bottom panel) was significantly lower in hearts
perfused with ASA or indomethacin than in the other groups.
Because PaO2 was identical in all cases, those hearts with low
recovery of coronary flow were trying to extract more oxygen
from the perfusate, a phenomenon again normalized by SQ
29548. These findings indicate that the lowered coronary flow
during work phase 2 was not matched to the oxygen demand of
the hearts with inhibited COX.
Ratio of lactate release to pyruvate consumption. The molar
ratio of lactate release to pyruvate consumption of the hearts
immediately before ischemia (work phase 1) was on the order
of ;1 (;1 mmol/min for each metabolite) and did not differ
between the groups (data not shown). With the beginning of
reperfusion (first 5 min), more lactate was released from the
hearts into the coronary venous effluent, whereas pyruvate
consumption decreased compared with that during work phase
1. This decrease resulted in a general increase in the ratio, as
depicted in Figure 4, indicating a shift toward anaerobic
metabolism. Comparison of these data with those of Table 2
and Figure 2 reveals a parallel relation to coronary resistance
and an inverse relation between recovery of function and the
postischemic ratio of lactate release to pyruvate consumption.
Thus, hearts with impaired reperfusion and poor postischemic
functional recovery (ASA- and indomethacin-treated hearts)
actually consumed less pyruvate and produced more lactate
during early reperfusion than did hearts of the other groups.
Release of 8-iso-PGF2a. Figure 5 (top panel) demonstrates
myocardial release of 8-iso-PGF2a during the various experi-
mental conditions. Preischemic control perfusion in the ab-
sence of any drugs was accompanied by a baseline 8-iso-PGF2a
release of 0.02 6 0.01 pg/ml in the coronary effluent, whereas
early reperfusion was associated with a substantial, more than
tenfold, increase in 8-iso-PGF2a release (Fig. 5). In hearts
perfused with the COX inhibitors ASA or indomethacin (10
mmol/liter), a comparable pattern of 8-iso-PGF2a release was
found, that is, an 8-iso-PGF2a efflux that was augmented
approximately tenfold during the initial part of the reperfusion
phase compared with the preischemic value. However, the rate
of formation of 8-iso-PGF2a in hearts perfused with ASA or
indomethacin was ;20-fold greater than that in control hearts
during the preischemic phase, and release was further en-
hanced after ischemia. Thus, ASA and indomethacin identi-
cally potentiated the release of 8-iso-PGF2a during early
reperfusion to levels .200-fold above the preischemic control
rate.
Content of 8-iso-PGF2a in postischemic heart tissue. Figure 5
(bottom panel) shows the tissue content of 8-iso-PGF2a imme-
diately after the end of work phase 2. Levels of 8-iso-PGF2a in
ASA-treated hearts were, on average, sevenfold those of
Figure 3. Evidence for microvascular disturbance of tissue oxygen-
ation after ischemia and reperfusion in hearts treated with ASA or
indomethacin. Top panel, Recovery of coronary flow (CF) during work
phase 2 (W2) versus work phase 1 (W1). Bottom panel, PvO2 during
work phase 2 (value of arterial perfusate constant at 630 mm Hg).
Hearts with significantly lower recovery of coronary flow were trying to
extract more oxygen from the perfusate, indicating a mismatch be-
tween coronary supply of oxygen and myocardial demand. Abbrevia-
tions and symbols as in Figure 1.*p , 0.05 versus CON and SQ groups.
†p , 0.05 versus ASA1SQ group.
Figure 4. Ratio of lactate release to pyruvate consumption after
ischemia, measured in coronary venous effluent during the first 5 min
of reperfusion (see Methods). Abbreviations and symbols as in Figure
1. *p , 0.05 versus CON, SQ and ASA1SQ groups.
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indomethacin-treated hearts approximately fivefold those of
control hearts.
Discussion
AA can be enzymatically oxidized in the heart principally
through the COX pathway (16). Under basal conditions the
concentration of nonesterified AA is low (2), but an accumu-
lation has been reported in the ischemic myocardium (17). As
a consequence, there is enhanced generation of eicosanoids
within the injured tissue, most notably TxA2 and PGI2 (18,19).
Although the role of COX products in the regulation of
coronary flow remains unresolved, reperfusion injury may be
influenced by the balance between the different metabolites of
AA and thus by inhibition of the COX pathway.
Known effects of COX inhibitors and thromboxane recep-
tor antagonists. In clinical studies, ASA has been shown (20)
to be efficacious in patients with ischemic heart disease,
probably because of the antiplatelet action of ASA. Although
it is an effective antithrombotic agent, a direct cardioprotective
effect of ASA on the ischemic myocardium itself has not yet
been demonstrated. On the contrary, a lack of effect of ASA on
myocardial infarct size in a canine model of coronary occlusion
was reported by Bonow et al. (9). Other investigators have
demonstrated that ASA even tended to increase infarct size
(21), with similar findings for indomethacin (22).
The poor results of COX inhibition by ASA-like drugs have
been related to the inhibition of PG formation, chiefly prosta-
cyclin (PGI2), with their vasodilatory and cardioprotective
properties (23). Because the effects of indomethacin on collat-
eral blood flow have been found to be inadequate (22),
increases in MVO2 or direct metabolic or cellular effects of
COX inhibition have been suggested (23). Closely related
questions arose in exploring the mechanisms underlying the
cardioprotective activity of TxA2 receptor antagonists, like SQ
29548, in myocardial ischemia–reperfusion injury (24). Surpris-
ingly, the beneficial action is not mitigated by aspirin-like drugs
(25), which can effectively block production of TxA2 and other
thromboxane receptor activators (PGG2, PGH2). However,
the receptor antagonists are not specific; SQ 29548 is very
effective in blocking coronary vasoconstriction and platelet
activation elicited by isoprostanes (8,26).
The isoprostanes. It is reasonable to speculate that inhibi-
tion of COX will cause shunting of AA toward production of
other biologically active metabolites (e.g., lipoxygenase prod-
ucts or nonenzymatic oxidation products) that could be vaso-
constrictors with thromboxane-like activity. One such group of
compounds is that of the isoprostanes (6), which are generated
by free radical mechanisms. Two representatives, 8-iso-PGF2a
and 8-iso-PGE2, were recently found (8) to be very potent
coronary vasoconstrictors, reducing flow by ;45% at submi-
cromolar concentrations. Interestingly, we found that SQ
29548 completely abrogated these vasoconstrictive actions,
suggesting that isoprostanes also act in the heart through TxA2
or closely related receptors. Furthermore, Delanty et al. (27)
reported urinary excretion of 8-iso-PGF2a to be increased,
both in a canine model of coronary thrombolysis immediately
after reperfusion and in patients with acute myocardial infarc-
tion given lytic therapy. However, causal involvement of iso-
prostanes in ischemia and reperfusion injury has not yet been
demonstrated. In the present study, the consequences of COX
inhibition were studied in an isolated heart model of controlled
myocardial ischemia and reperfusion. Our results reveal a
significant impairment of ventricular recovery in hearts treated
with either ASA and indomethacin. The deleterious effects
were completely abolished in the presence of SQ 29548, and
COX inhibition was associated with a greatly augmented
release of 8-iso-PGF2a before ischemia but especially in the
early reperfusion period. Moreover, postischemic tissue levels
of the isoprostane were significantly higher in hearts treated
with ASA or indomethacin.
Figure 5. Top panel, Cardiac release of 8-iso-PGF2a (in pg/ml) as
measured in coronary effluent during the last 5 min of preischemic
work (work phase 1 [W1]) and during the first 5 min of reperfusion
(R1). Bottom panel, Tissue content of 8-iso-PGF2a (in pg/mg dry
weight [dwt]) at the end of work phase 2. Perfusion was with KHB
without (control [CON]) or with 100 mmol/liter ASA or 10 mmol/liter
indomethacin (INDO), respectively. Data shown are mean value 6
SEM of four hearts under each condition. In all groups, reperfusion
was associated with a dramatic increase in 8-iso-PGF2a generation.
Treatment of hearts with ASA or indomethacin was associated with
markedly higher generation of 8-iso-PGF2a, especially during the first
5 min of reperfusion, as well as significantly higher postischemic tissue
levels than in control hearts. *p , 0.05 versus work phase 1. †p , 0.05
versus control group.
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Mechanism of action. The ASA- and indomethacin-
treated hearts, although identical to control hearts before
ischemia, were characterized by significantly lower postisch-
emic coronary flow and aortic flow and performance of EHW,
indicating that inhibition of COX impaired ischemic tolerance
or augmented reperfusion injury, or both. It could be argued
that the more pronounced decrease of coronary flow in ASA-
and indomethacin-treated hearts during work phase 2 than in
control hearts could have been appropriate and was prompted
by the depressed postischemic work performance. Coronary
flow is normally regulated to maintain a balance between
myocardial oxygen supply and demand (28). Indeed, the
significantly lower coronary flow in ASA- and indomethacin-
treated hearts was associated with a decrease in MVO2.
However, there was also a change in oxygen extraction. With
ASA and indomethacin, the coronary arterovenous oxygen
difference widened, indicating a significant increase in oxygen
extraction by the myocardium. This increase implies that the
postischemic work performance was limited by coronary oxy-
gen supply: Had coronary flow been adequate, there would
have been no need for greater extraction. In support of this
conclusion, indomethacin has reportedly reduced myocardial
oxygen supply to postischemic rabbit hearts in vitro (29). A
causal link to the isoprostanes is seen on analysis of the
coronary flow changes and metabolic variables in the presence
of SQ 29548. Postischemic coronary flow, MVO2 and coronary
PvO2 values in the groups receiving ASA plus SQ 29548 and
indomethacin plus SQ 29548 at the onset of reperfusion (i.e.,
with blocked isoprostane effects) were all in the range observed
in control hearts. Because applying SQ 29548 only at the onset
of reperfusion was as effective as it being present during
ischemia as well, the effect of COX inhibition would seem to
relate more to reperfusion injury.
Further evidence for an isoprostane-induced coronary flow
limitation comes from the early reperfusion period. Higher
levels of coronary resistance occurred in hearts treated with
ASA or indomethacin than in the control hearts but not in the
presence of SQ 29548. Because SQ 29548 given alone did not
notably affect postischemic vascular resistance or coronary
flow, this drug does not possess intrinsic vasodilator activity.
Moreover, hearts with COX inhibition were characterized by
increased release of lactate as opposed to a suppressed con-
sumption of pyruvate. The ratio of lactate release to pyruvate
consumption accentuates a shift toward anaerobic metabolism
and has been found to correlate well with myocardial meta-
bolic changes associated with hypoxia (30). The demonstrated
relation between vascular resistance, release of 8-iso-PGF2a
and the lactate/pyruvate ratio during early reperfusion suggests
that there is a disturbance of microvascular perfusion in the
ASA and indomethacin groups. The higher level of vascular
resistance in work phase 2 in those groups also suggests a
vasoconstrictor effect persisting throughout reperfusion. Perti-
nently, an increase in coronary resistance has been reported in
response to COX inhibition (31). In patients with coronary
artery disease, indomethacin therapy was also accompanied by
a fall in coronary flow that was due to a significant increase in
coronary resistance (32). In the isolated rat heart, indometh-
acin suppressed the increase in coronary flow induced by
hypoxia, and the simultaneous release of unknown vasocon-
stricting factors was proposed (3).
It is noteworthy that both COX inhibitors failed to affect
preischemic coronary flow, which suggests that the increase in
isoprostane formation under basal conditions is insufficient to
cause coronary vasoconstriction in the intact heart. However,
with the advent of ischemia–reperfusion, generation of AA and
oxygen free radicals is greatly exacerbated. Then, shunting AA
away from the COX pathway may lead to critical levels of
vasoconstricting metabolites. Owing to their lipophilic nature,
the isoprostanes measured in the saline effluent are probably
only the “tip of the iceberg.” Indeed, we found postischemic
levels of 8-iso-PGF2a in the ventricular tissue of the ASA- and
indomethacin-treated hearts to be five to seven times higher
than in control hearts. The levels of 200 to 300 pg/mg dry
weight convert to concentrations of up to 2 3 1027 mol/liter, if
based on tissue water (85% of tissue wet weight). Such
concentrations have been shown to decrease coronary flow
significantly when infused (8).
Conclusions. The data presented here suggest that the
potentially deleterious effects of COX inhibitors reside in the
shifting of AA metabolism, away from PG formation and
toward the isoprostanes. Aggravation of ischemia–reperfusion
injury by these potent vasoconstrictor compounds could be
clinically relevant, because increasing numbers of patients with
coronary heart disease routinely take ASA. Despite obvious
reservations concerning extrapolation of the present model to
the in vivo situation, especially with respect to questions of
drug concentration, COX inhibitors should probably be used
with some caution in patients with severe coronary artery
disease. The protection observed with the TxA2 receptor
antagonist SQ 29548 against isoprostane-induced vasoconstric-
tion, particularly during reperfusion, may be a therapeutically
exploitable principle.
We thank Dora Kiesl, Sabine D’Avis and Denice Deck for expert technical
assistance.
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